Company Brainstorm Cell Therapeutics Inc OTC Bulletin Board

Equities

US10501E2019

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Inactive Instrument

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

17/04	Brainstorm Cell Therapeutics Inc. Announces Step Down of Stacy Lindborg as Co-CEO, Effective as of May 9, 2024	CI
17/04	Brainstorm Cell Therapeutics Inc. Announces Management Changes	CI

BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimerâs disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.

Managers	Title	Age	Since
Chaim Lebovits CEO	Chief Executive Officer	53	01/07/01
Alla Patlis DFI	Director of Finance/CFO	37	23/12/23
Netta Blondheim-Shraga CTO	Chief Tech/Sci/R&D Officer	-	12/22/12
Bob Dagher CTO	Chief Tech/Sci/R&D Officer	55	17/23/17
Yael Gothelf CTO	Chief Tech/Sci/R&D Officer	-	01/07/01
Stacy Lindborg BRD	Director/Board Member	53	01/20/01
Uri Yablonka BRD	Director/Board Member	47	06/14/06
Antal Pearl-Lendner LAW	General Counsel	-	12/22/12
Mary Kay Turner LAW	General Counsel	-	07/17/07
Yossef Levy PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Irit Arbel FOU	Founder	64	22/00/22
Uri Yablonka BRD	Director/Board Member	47	06/14/06
Jacob Frenkel CHM	Chairman	81	30/20/30
Menghisteab Bairu BRD	Director/Board Member	63	28/21/28
Anthony J. Polverino BRD	Director/Board Member	61	05/18/05
Stacy Lindborg BRD	Director/Board Member	53	01/20/01
Nir Naor BRD	Director/Board Member	50	20/23/20

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	68,447,193	60,806,674 ( 88.84 %)	0	88.84 %

Name	Equities	%	Valuation
Chaim Lebovits 4.537 %	3,100,712	4.537 %	2 M $
Kevin Ness 4.477 %	3,060,000	4.477 %	2 M $
Abbhi Investments LLC 3.184 %	2,175,853	3.184 %	1 M $
Vanguard Global Advisers LLC 2.050 %	1,400,993	2.050 %	745 328 $
BlackRock Institutional Trust Co. NA 0.7067 %	482,985	0.7067 %	256 948 $
Stacy Lindborg 0.6196 %	423,435	0.6196 %	225 267 $
Geode Capital Management LLC 0.5224 %	357,041	0.5224 %	189 946 $
Liberty Wealth Management LLC 0.4977 %	340,150	0.4977 %	180 960 $
Bob Dagher 0.3702 %	253,000	0.3702 %	134 596 $
Weaver Consulting Group LLC 0.2917 %	199,356	0.2917 %	106 057 $

Brainstorm Cell Therapeutics, Inc.

1325 Avenue of Americas 28th floor

10019, New York

+201 488 0460

http://www.brainstorm-cell.com

address Brainstorm Cell Therapeutics Inc

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+33.37%	50.85B
IQVIA HOLDINGS INC.	+1.55%	42.82B
LONZA GROUP AG	+49.17%	42.03B
CELLTRION, INC.	-4.22%	29.55B
ICON PUBLIC LIMITED COMPANY	+11.57%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	19.13B
BIO-TECHNE CORPORATION	+7.36%	13.05B
MEDPACE HOLDINGS, INC.	+28.30%	12.16B
UNITED THERAPEUTICS CORPORATION	+23.80%	12.08B

Other Biotechnology & Medical Research